UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION

                       Washington, D.C. 20549
                           FORM 10-QSB

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
      OF THE SECURITIES AND EXCHANGE ACT OF 1934
      For the Quarter ended June 30, 2000

[ ]   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
      EXCHANGE ACT
      For the transition period               to
                                ----------       ----------

                 Commission file number - 000-26423

                   INFECTECH, INC.
Exact name of Registrant as specified in its charter)

          DELAWARE                                      34-1760019
(State or other jurisdiction of                   (I.R.S. Employer
incorporation or organization                      Identification
                                                       Number)

Suite Two, 87 Stambaugh Avenue, Sharon, PA             16146
(Address of principal executive offices)             (Zip Code)

                      (724) 346-1302
            (Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities
and Exchange Act of 1934 during the preceding twelve months (or such
shorter period that the Registrant was required to file such reports),
and (2) has been subject to file such filing requirements for the past
thirty days.

Yes    x      No
    ------       ------

Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the close of the period covered by this
report:

                   6,822,185 Shares of Common Stock ($.02 par value)
                               (Title of Class)


Transitional Small Business Disclosure Format (check one):
    Yes           No    x
       -------       -------











<PAGE>2

                        Infectech, Inc.


PART I:      Financial Information

                     ITEM 1 - Financial statements

                     ITEM 2 - Management's' discussion and analysis of
                     financial condition and results of operations

PART II:      Other Information

                     ITEM 6 - Exhibits and Reports on Form 8-K










<PAGE>3

                           PART I

Item 1. Financial Statements:



CONSOLIDATED BALANCE SHEETS
INFECTECH, INC.  AND SUBSIDIARY
(A DEVELOPMENT STAGE ENTERPRISE)
<TABLE>
<CAPTION>
                                                            Unaudited                     Audited
                                                             June 30,                     Dec 31,
ASSETS                                                         2000                        1999
<S>                                                            <C>                           <C>
CURRENT ASSETS
Cash and cash equivalents                                  $    1,125                    $  19,044

EQUIPMENT
Medical equipment                                              45,968                       45,968
Less accumulated depreciation                                  25,753                       22,470
                                                              -------                       ------
NET EQUIPMENT                                                  20,215                       23,498

OTHER ASSETS
Deposit                                                         2,002                        2,002

Patent costs, net of accumulated amortization
of $148,309 in 2000 and $126,190 in 1999                      575,759                      590,409
                                                              -------                      -------
TOTAL OTHER ASSETS                                            577,761                      592,411
                                                             --------                      -------
                                                             $599,101                     $634,953
                                                             ========                     ========
LIABILITIES AND STOCKHOLDERS EQUITY

CURRENT LIABILITIES
Accounts payable                                             $  93,133                    $ 76,887
Accrued payroll taxes                                              444                       2,205
Accrued state taxes                                              2,468                       2,468
                                                             ---------                    --------
TOTAL CURRENT LIABILITIES                                       96,045                      81,560
                                                             ---------                      ------
LONG-TERM DEBT
Notes payables                                                  25,400                           0

STOCKHOLDERS EQUITY
Common stock -$.02 par value per share
Authorized 20,000,000 shares; issued and
outstanding 6,822,185 shares in 2000
and 6,629,064 shares in 1999                                    136,444                    132,581
Additional paid-in capital                                    2,824,502                  2,490,163
Deficit accumulated during the development stage             (2,483,290)                (2,069,351)
                                                             ----------                  ----------
TOTAL STOCKHOLDERS EQUITY                                       477,656                    553,393
                                                              ---------                  ---------
                                                              $ 599,101                  $ 634,953
                                                              =========                  ==========
</TABLE>

See accompanying notes to consolidated financial statements



<PAGE>4

CONSOLIDATED STATEMENTS OF OPERATIONS

INFECTECH, INC.  AND SUBSIDIARY
(A DEVELOPMENT STAGE ENTERPRISE)
UNAUDITED
<TABLE>
<CAPTION>
                                                                                                  Period from
                                                                                                June 21, 1989
                            Three months ended June 30     Six months ended June 30            (Inception) to
OPERATING INCOME               2000             1999         2000             1999              June 30, 2000
                            ---------------------------------------------------------------------------------
<S>                            <C>                <C>          <C>             <C>                    <C>
Sales and Royalties          $10,895          $      0     $ 18,395        $       0             $   35,354

OPERATING EXPENSES
Research and development       8,539            27,384        8,539           34,989                282,959
Wages                          1,243             7,402      155,560           13,079                427,296
Telephone                      2,386             5,561        5,036            6,450                 45,375
Office Expense                 3,032             5,765        6,192            8,755                 41,849
Insurance                          0                 0            0               51                 18,567
Legal and accounting               0            14,277        4,557           14,718                279,167
Travel                           700            41,880        2,106            5,657                 84,068
Payroll taxes                      0               708          176            1,300                 11,543
State and local taxes              0                 0          534            2,621                 16,813
Amortization                  11,182             9,600       22,119           18,525                151,150
Depreciation                   1,641             1,554        3,283            3,108                 25,754
Rent                           7,439             3,431       12,938            8,446                108,505
Consulting and professional
  Fees                        89,973             4,331      197,739           15,941                826,200
Public relations               1,000            26,810        6,971           26,810                165,258
Royalties                      3,290                 0        5,207                0                  9,035
Miscellaneous operating expenses 612             2,451        1,346            5,209                 37,336
MD-diagnostics com. Expenses      99            30,614          198           30,614                 43,028
                             -------           --------     -------          -------              ---------
Total operating expenses     131,138           144,768      432,501          196,273              2,573,903
                            --------           -------      -------          -------              ---------
Loss from operations        (102,243)         (144,768)    (414,106)        (196,273)            (2,538,549)

OTHER INCOME (DEDUCTIONS)
Interest expense                   0                  0           0                0                   (661)
Interest Income                   26              1,998         167            4,061                 55,920
                           ----------          ---------  ----------        --------            ------------
Net Loss                   $(120,217)         $(142,770)  $(413,939)       $(192,212)           $(2,483,290)
                           =========          =========   =========        =========            ============
BASIC LOSS PER SHARE       $    (.02)         $    (.02)  $    (.06)       $    (.03)
                           ==========         ==========  ==========       ==========
WEIGHTED AVERAGE SHARES   6,733,823          6,487,617   6,765,385        6,427,845
</TABLE>

See accompanying notes to consolidated financial statements



<PAGE>5

CONSOLIDATED STATEMENTS OF CASH FLOWS

INFECTECH, INC.  AND SUBSIDIARY
(A DEVELOPMENT STAGE ENTERPRISE)
UNAUDITED
<TABLE>
<CAPTION>
                                                                                           Period from
                                                                                         June 21, 1989
                                         Six months ended June 30                       (Inception) to
                                         2000                1999                        June 30, 2000
<S>                                       <C>                  <C>                           <C>
CASH FLOWS FROM OPERATING ACTIVITIES

Net loss                                 $ (413,939)         $ (192,212)                 $ (2,483,290)
Adjustments to reconcile net loss to
Net cash used in operating activities:
Amortization                                 22,119              18,525                       151,150
Depreciation                                  3,282               3,108                        25,753
Increase (decrease) in payables              16,245              11,373                        91,338
Increase (decrease) in accrued expenses      (1,760)                663                         3,975
Expenses exchanged for capital              323,202                   0                     1,134,515
                                           --------            --------                   -----------
Net cash used in operating activities       (50,851)           (158,543)                   (1,076,559)
                                           --------             -------                   -----------

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of equipment                             0                   0                       (45,969)
Patent Costs                                 (7,468)            (43,488)                     (724,908)
Increase in deposits                              0                 (50)                       (2,002)
                                             -------            -------                      ---------
Net cash used in investing activities        (7,468)            (43,538)                     (772,879)
                                             ------             -------                       --------
CASH FLOWS FROM FINANCING ACTIVITIES
Fees in connection with issuance of stock         0              (2,585)                      (87,348)
Proceeds from issuance of long-term debt     25,400                   0                       195,965
Proceeds from issuance of common stock       15,000             133,234                     1,741,946
                                             ------            --------                     ---------
Net cash provided by financing activities    40,400             130,649                     1,850,563
                                            -------             -------                     ---------
Net decrease in cash and cash equivalents   (17,919)            (71,432)                        1,125

CASH AND CASH EQUIVALENTS
Beginning of period                          19,044             217,295                             0
End of period                            $    1,125            $145,863                   $     1,125
                                         ==========            ========                   ===========
CASH WAS PAID FOR
Interest                                 $        0            $      0                   $       661
                                         ==========           =========                   ===========
</TABLE>
See accompanying notes to consolidated financial statements




<PAGE>

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

INFECTECH, INC.  AND SUBSIDARY
(A DEVELOPMENT STAGE ENTERPRISE)
SIX MONTHS ENDED JUNE 30,2000
UNAUDITED

NOTE A - BASIS OF PRESENTATION

These unaudited financial statements are those of a development
stage company, Infectech, Inc., that was incorporated in 1989 to
develop diagnostic tests for infectious diseases and one 95%
owned subsidiary.  The accompanying unaudited financial
statements have been prepared in accordance with generally
accepted accounting principles for interim financial information
and with instructions to form 10-QSB.  Accordingly, they do not
include all of the information and footnotes required by
generally accepted accounting principles for complete financial
statements.  In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary
have been made for the fair presentation of the company's
results for the six month period ended June 30, 2000.  These
results are not necessarily indicative of the results that may
be expected for the year ended December 31, 2000.









<PAGE>7

              Infectech, Inc.

PART I (cont.)

Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations:

Trends and Uncertainties.  Demand for Infectech's products will be
dependent on, among other things, market acceptance of Infectech's
concept, the quality of its products, government approval and general
economic conditions, which are cyclical in nature.  Inasmuch as a
major portion of Infectech's activities will be the receipt of
revenues from the sales of its products, Infectech's business
operations may be adversely affected by Infectech's competitors and
prolonged recessionary periods.

Capital and Source of Liquidity.   Infectech requires substantial
capital in order to meet its ongoing corporate obligations and in
order to continue and expand its current and strategic business plans.
Initial working capital has been obtained by the private sale of
Infectech's common shares from November 1996 to present.

For the six months ended June 30, 2000, Infectech received proceeds
from the issuance of long term debt of $25,400 and proceeds from the
issuance of common stock of $15,000 resulting in net cash provided by
financing activities of $40,400 for the six months ended June 30,
2000.

For the six months ended June 30, 1999, Infectech had fees in
connection with the issuance of stock of $2,585 and had proceeds from
the issuance of common stock of $133,234. As a result, Infectech had
net cash provided by financing activities of $130,649 for the six
months ended June 30, 1999.

For the six months ended June 30, 2000, Infectech had patent costs of
$7,468 resulting in net cash used in investing activities of $7,468.
Infectech anticipates that costs associated with product testing and
development will continue to increase.

For the six months ended June 30, 1999, Infectech had patent costs of
$43,488.   Infectech had an increase in deposits of $50.  As a result,
Infectech had net cash used in investing activities of $43,538 for the
six months ended June 30, 1999.

On a long-term basis, liquidity is dependent on continuation and
expansion of operation and receipt of revenues, additional infusions
of capital and debt financing.   Infectech believes that additional
capital and debt financing in the short term will allow Infectech to
increase its marketing and sales efforts and thereafter result in
increased revenue and greater liquidity in the long term.  However,
there can be no assurance that Infectech will be able to obtain
additional equity or debt financing in the future, if at all.

Results of Operations.   Since inception, Infectech has not received
any material revenues from operations.   Sales and royalties for the
six months ended June 30, 2000 were $18,395.

Research and development expenses were $8,539 for the six months ended
June 30, 2000 compared to $34,989 for the six months ended June 30,
1999.   This decrease was due to research activities for its patents
being shifted to work done internally in 1999.   Wages increased to
$155,560 for the six months ended June 30, 2000 from $13,079 for the
six months ended June 30, 1999.   This was the result from one
employee working full time in research and development starting the
later part of 1998.   Legal and accounting increased to $4,557 for the
six months ended June 30, 2000 compared to $14,718 for the six months
ended June 30, 1999.

Consulting and professional fees increased to $197,739 for the six
months ended June 30, 2000 from $15,941 for the six months ended June
30, 1999.   This increase is due to increasing activity with
consultants regarding marketing and commercialization of Infectech's
product.

Public relation expenses were $6,971 for the six months ended June 30,
2000 versus $26,810 for the six months ended June 30, 1999.
Infectech incurred $198 in expenses for the six months ended June 30,
2000 in connection with its subsidiary, MD-Diagnostics.com, Inc. to
develop internet sites for medical diagnostics compared to $30,614 for
the six months ended June 30, 1999.

<PAGE>8

Plan of Operation. Infectech is in the development stage and has not
conducted any significant operations to date and has received only
minimal royalty revenues.  Infectech may experience problems; delays,
expenses and difficulties sometimes encountered by an enterprise in
Infectech's stage of development, many of which are beyond Infectech's
control.  These include, but are not limited to, unanticipated
problems relating to product development, testing, regulatory
compliance, manufacturing costs, production and marketing problems,
additional costs and expenses that may exceed current estimates and
competition.

Infectech has funding needs of approximately $1.2 million.  Infectech
shall seek equity or debt financing for intellectual Property
($30,000), research and development for Tuberculosis Pseudomonas
($814,400), legal expense for patents ($263,419) and internet research
and development ($50,000).  This does not include Infectech's working
capital need.   Research and development expenses will be dependent on
the availability of funds.   Infectech does not expect any additional
purchases of plant and equipment.   There are no expected significant
changes in the number of employees.  If Infectech obtained funding,
support type of employees such as secretarial, etc, may be required.

As of June 30, 2000, Infectech had very little working capital.
Infectech expects to use this minimum capital to continue research and
development of patents and for the costs associated with executing an
initial public stock offering.  Infectech believes that the net
proceeds from equity financing together with revenues from operations,
if any, will be sufficient to meet its anticipated cash needs for
working capital and capital expenditures until approximately December
2001.  There can be no assurance, however, that the net proceeds from
equity financing will not be expended prior thereto due to
unanticipated changes in economic conditions or other unforeseen
circumstances.  Unless growth in Infectech's revenues from operations
substantially exceeds management's current expectations, by
approximately December 2001, Infectech will be required to seek
additional equity or debt financing to fund the costs of its
operations, including continued development of its products.  There
can be no assurance that additional financing will be available or
that, if available, such financing will be on acceptable terms to
enable Infectech to complete development of or commercialize any of
its proposed products or technologies.

Infectech is not delinquent in any of its obligations even though
Infectech has generated limited operating revenues.    Infectech
intends to market its products utilizing cash made available from the
private and public sale of its securities. Infectech's management is
of the opinion that revenues from the sale of its products and the
proceeds of the sales of its securities will be sufficient to pay its
expenses until its business plan can be fully implemented.





<PAGE>9

                     PART II


Item 6. Exhibits and Reports on Form 8-K

(a)   Exhibits (numbered in accordance with Item 601 of
      Regulation S-K)

      None

(b)   Reports on Form 8-K

None







                           SIGNATURE

Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly
authorized.


Date:                            /s/ Mitchell Felder, MD
                                 ----------------------------
                                 Mitchell Felder, President


April 5, 2001